The latest three-way merger bid for bookmaker William Hill fell flat with shareholders, after the group rejected a revised proposal from 888 Holdings and The Rank Group for a potential combination of the three companies.
In a statement Monday, the board called the bid “highly opportunistic,” mirroring the rejection of last week’s £3.6bn bid.
The board said it continued to believe that a combination of William Hill with 888 and Rank will not enhance its strategic positioning or deliver superior value for shareholders.
The revised proposal equates to around 352p per share, representing a 12% premium, and would mean William Hill shareholders owned 48.8% of the combined group. The previous offer stood at 339p per share.
William Hill said the revised proposal would continue to present “significant risk” for its shareholders due to the highly complicated three-way combination at a very low premium.
“The board continues to believe we have a strong team to deliver superior value to our shareholders and trading at the start of the second half gives us renewed confidence in our stand-alone strategy,” said chairman Gareth Davis.
“This revised proposal continues to substantially undervalue the company and the cash element of the proposal has not changed. Therefore, the Board sees no merit in engaging.”
Last week, analysts raised concern over the £2.2bn debt the proposed group would have to assume to fund the cash element of the deal.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas